Skip to main content
News > News > Open Therapeutics To Open Therapeutic Drug Opportunities

Open Therapeutics To Open Therapeutic Drug Opportunities

Open Therapeutics To Freely Open Therapeutic Drug Opportunities

Capable and responsible researchers to freely gain technologies enabling their discovery and development of pharmaceuticals

 

CINCINNATI, Ohio, USA– September 28, 2015 – Open Therapeutics announces the opening of significant drug discovery technologies to global researchers in early 2016. Using a form of crowd-sourcing, biopharmaceutical researchers will have free access to synthetic biology-based technologies.

Open Therapeutics™ is an agnostic endeavor to reduce the cost and risk of developing and deploying therapeutics by stimulating an “open source, economies of scale model”. This should lower the cost of life-saving therapeutics and make them globally available, particularly for underserved populations.

Open Therapeutics is a response to two sets of key findings. The first, from the Tufts University Center for the Study of Drug Development, is the “cost to develop and win marketing approval for a new drug is $2.6 billion.” The second, recently reported by Deloitte®, is that “drugs sourced via open innovation are three times more likely to achieve late-phase clinical success versus those cultivated under an in-house, closed-model approach.”

According to Open Therapeutics CEO, Jason E. Barkeloo, “Open Therapeutics seeks to breakdown the silos limiting scientists. By freely providing promising and proven biopharma technologies, Open Therapeutics can unchain the scientific community’s potential. We believe freeing researchers from the confidentiality framework promises to increase global public health and patient treatment outcomes.”

The initial technologies being freely provided to global researchers include bacterial and viral neoplasm lytic and cancer lytic (oncolytics), cancer biomarker expression and secretion, and essential proteins that can provide collaborating researchers with targets for antibiotic and oncology drugs.

More information is at the Open Therapeutics product page.

____________________________________________

About Open Therapeutics LLC
Open Therapeutics is a seven-year old global biotechnology firm that rapidly prototypes synthetic biology products for expert industrial and academic clients.  We create open and proprietary bacterial (BactoBots), viral (ViruBots) for water, chemical, and pharmaceutical industries. We also discover essential proteins for developing antibiotic and anticancer therapeutics. The Company is headquartered in Cincinnati, Ohio with laboratory operations in Covington, Kentucky, USA, and Madrid, Spain via its strategic partner, Bacmine SL, (www.bacmine.com).

For more information on Open Therapeutics, visit its web site at http://staging.jaded-glass.flywheelsites.com.

Contact:
Jason E. Barkeloo
+1.513.252.2901
https://twitter.com/MicrobialBot or @MicrobialBot

###

[Click here for the PDF version.]

We Believe

Open Therapeutics crowdsources orphan and dormant therapeutic intellectual properties (IP) to scientists around the world. The goal is advancing research that ordinarily has not generated a public value or been recognized. This approach particularly helps underserved scientists to collaborate with their more financially capable colleagues.

How open science helps researchers succeed:

Open access, open data, open source, and other open scholarship practices are growing in popularity and necessity. However, widespread adoption of these practices has not yet been achieved. One reason is that researchers are uncertain about how sharing their work will affect their careers.

The review of the literature demonstrates that open science is associated with increases in citations, media attention, potential collaborators, job opportunities, and funding opportunities. These findings are evidence that open science practices bring significant benefits to researchers relative to more traditional closed practices.

Secured By miniOrange